ETX-197
- Generic Name
- ETX-197
BeiGene to Present Extensive Hematology Data at EHA 2025, Showcasing BRUKINSA and Next-Generation Therapies
• BeiGene will present 31 abstracts at the European Hematology Association Congress in Milan, highlighting data from its BTK inhibitor BRUKINSA and investigational pipeline assets sonrotoclax and BGB-16673.
• The company's next-generation pipeline assets have demonstrated promising clinical activity and safety profiles across multiple B-cell malignancies, with over 2,500 patients enrolled globally in clinical trials.
• Four oral presentations will feature updated results from clinical studies of BGB-16673 in CLL/SLL and WM, as well as sonrotoclax in combination with BRUKINSA in R/R CLL/SLL and R/R MCL.
FDA Clears Ensem Therapeutics' IND for Novel PI3Kα Inhibitor ETX-636 for Advanced Cancer Treatment
• Ensem Therapeutics received FDA clearance for ETX-636, a first-in-class allosteric pan-mutant-selective PI3Kα inhibitor and degrader, with clinical trials set to begin in Q2 2025 for patients with PI3Kα-mutated tumors.
• ETX-636 selectively targets mutant PI3Kα while sparing wildtype PI3Kα, potentially avoiding hyperglycemia that limits current PI3Kα inhibitors, addressing a significant challenge in treating HR+/HER2- breast cancers.
• The upcoming Phase 1/2 trial will evaluate ETX-636 as monotherapy and in combination with fulvestrant in advanced solid tumors, with preclinical data to be presented at the AACR Annual Meeting on April 28, 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath